PANBELA THERAPEUTICS INC (PBLA) Stock News
NASDAQ:PBLA - Nasdaq - US69833W4042 - Common Stock - Currency: USD
PBLA Latest News, Press Relases and Analysis
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the second quarter...
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024
PBLA stock results show that Panbela Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the first quarter ...
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Panbela Therapeutics (NASDAQ:PBLA) just reported results for the fourth quarter...
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin American
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024
PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Developed in collaboration with Sanofi.
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial's lower-than-expected event rate suggests improved survival outcomes
Panbela Announces Poster Presentation at American Association for Cancer Research:
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
Panbela Announces Transfer to OTCQB Market
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023
PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Panbela Therapeutics regains compliance with Nasdaq (NASDAQ:PBLA)
Panbela Therapeutics (PBLA) regains compliance with Nasdaq for bid price and publicly held shares, marking a positive development for the clinical stage...
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
Panbela Therapeutics closes ~$9M public offering of shares (NASDAQ:PBLA)
Biopharmaceutical company Panbela Therapeutics has closed ~$9M public offering of ~4.4M shares priced at $2.06 per share.
Panbela Announces Closing of Approximately $9.0 Million Public Offering
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...
Panbela Announces Closing of Approximately $9.0 Million Public Offering
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Why Is Aclarion (ACON) Stock Down 16% Today?
Aclarion stock is falling on Monday after the company issued 500,000 shares of ACON to cover principal and accrued interest from notes.
Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?
Panbela Therapeutics stock is falling on Monday after pricing a public offering for PBLA shares well below its price closing price.